



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

INTERIM RESULTS ANNOUNCEMENT
FOR THE SIX MONTHS ENDED 30 JUNE 2024

CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful considerations. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement, for which the directors (the “Directors”) of Biosino Bio-Technology and Science Incorporation (the “Company”, together with its subsidiaries, the “Group”) collectively and individually accept full responsibilities, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the “GEM Listing Rules”) for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

The board of Directors (the “Board”) announced the unaudited consolidated statement of profit or loss of the Group for the six months ended 30 June 2024 and the unaudited condensed consolidated statement of financial position of the Group as at 30 June 2024, together with the comparative figures in 2023, as follows:

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2024

		Six months ended	
		30 June	
		2024	2023
	<i>Notes</i>	Unaudited	Unaudited
		RMB'000	RMB'000
REVENUE	4	133,828	139,146
Cost of sales		<u>(75,297)</u>	<u>(72,470)</u>
Gross profit		58,531	66,676
Other income and gains		1,247	405
Selling and distribution expenses		(31,629)	(30,710)
Administrative expenses		(22,277)	(25,795)
Research and development expenses		(16,870)	(15,953)
Other expenses		<u>(953)</u>	<u>(113)</u>
LOSS FROM OPERATING ACTIVITIES	5	(11,951)	(5,490)
Finance costs		(4,190)	(2,954)
Share of profits and losses of:			
Joint ventures		(9)	(29)
Associates		5	2,663
LOSS BEFORE TAX		(16,145)	(5,810)
Income tax expense	6	<u>(2,169)</u>	<u>(2,201)</u>
LOSS FOR THE PERIOD		(18,314)	(8,011)
Attributable to:			
Owners of the parent		(13,182)	(5,423)
Non-controlling interests		<u>(5,132)</u>	<u>(2,588)</u>
		<u>(18,314)</u>	<u>(8,011)</u>
LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY	7		
– Basic and diluted (RMB)		<u>(0.091)</u>	<u>(0.037)</u>

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2024

	Six months ended	
	30 June	
	2024	2023
	Unaudited	Unaudited
	<i>RMB'000</i>	<i>RMB'000</i>
LOSS FOR THE PERIOD AND TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	(18,337)	(7,956)
Attributable to:		
Owners of the parent	(13,205)	(5,368)
Non-controlling interests	(5,132)	(2,588)
	<u>(18,337)</u>	<u>(7,956)</u>

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 30 June 2024

		30 June 2024	31 December 2023
		Unaudited	Audited
	<i>Notes</i>	RMB'000	RMB'000
NON-CURRENT ASSETS			
Property, plant and equipment		77,076	74,361
Investment properties		20,352	20,713
Right-of-use assets		7,813	9,318
Other intangible assets		27,884	26,540
Investments in joint ventures		12,244	11,953
Investments in associates		66,502	66,497
Long-term receivables		500	500
Deferred tax assets		181	3,229
		<hr/>	<hr/>
Total non-current assets		212,552	213,111
		<hr/>	<hr/>
CURRENT ASSETS			
Inventories		63,840	60,410
Trade and bills receivables	<i>9</i>	177,518	179,798
Prepayments, other receivables and other assets		47,353	46,522
Cash and cash equivalents		35,076	63,410
		<hr/>	<hr/>
Total current assets		323,787	350,140
		<hr/> <hr/>	<hr/> <hr/>

		30 June 2024	31 December 2023
		Unaudited	Audited
	<i>Notes</i>	RMB'000	RMB'000
CURRENT LIABILITIES			
Trade payables	<i>10</i>	108,517	111,540
Other payables and accruals		60,436	63,009
Interest-bearing bank and other borrowings	<i>11</i>	136,382	140,737
Lease liabilities		5,241	5,241
Tax payable		509	220
		<hr/>	<hr/>
Total current liabilities		311,085	320,747
		<hr/>	<hr/>
NET CURRENT ASSETS		12,702	29,393
		<hr/>	<hr/>
TOTAL ASSETS LESS CURRENT LIABILITIES		225,254	242,504
		<hr/>	<hr/>
NON-CURRENT LIABILITIES			
Interest-bearing bank and other borrowings		4,930	1,980
Other payables		2,205	–
Deferred income		16	66
Lease liabilities		2,565	3,492
Deferred tax liabilities		2,471	5,562
		<hr/>	<hr/>
Total non-current liabilities		12,187	11,100
		<hr/>	<hr/>
Net assets		213,067	231,404
		<hr/> <hr/>	<hr/> <hr/>
EQUITY			
Equity attributable to owners of the parent			
Share capital	<i>12</i>	144,707	144,707
Reserves		52,475	65,680
		<hr/>	<hr/>
		197,182	210,387
Non-controlling interests		15,885	21,017
		<hr/>	<hr/>
Total equity		213,067	231,404
		<hr/> <hr/>	<hr/> <hr/>

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2024

	Attributable to owners of the parent								Total equity Unaudited RMB'000
	Share capital Unaudited RMB'000	Capital reserve* Unaudited RMB'000	Statutory reserve* Unaudited RMB'000	Exchange reserve* Unaudited RMB'000	Fair value reserve of financial assets at fair value through other comprehensive income* Unaudited RMB'000	Accumulated losses* Unaudited RMB'000	Total Unaudited RMB'000	Non-controlling interests Unaudited RMB'000	
At 1 January 2024	144,707	140,820	49,459	(114)	(1,005)	(123,480)	210,387	21,017	231,404
Loss for the period	-	-	-	-	-	(13,182)	(13,182)	(5,132)	(18,314)
Exchange differences on translation of foreign operations	-	-	-	(23)	-	-	(23)	-	(23)
Total comprehensive loss for the period	-	-	-	(23)	-	(13,182)	(13,205)	(5,132)	(18,337)
At 30 June 2024	<u>144,707</u>	<u>140,820</u>	<u>49,459</u>	<u>(137)</u>	<u>(1,005)</u>	<u>(136,662)</u>	<u>197,182</u>	<u>15,885</u>	<u>213,067</u>
At 1 January 2023	144,707	124,672	47,978	(152)	(1,005)	(110,351)	205,849	28,258	234,107
Loss for the period	-	-	-	-	-	(5,423)	(5,423)	(2,588)	(8,011)
Exchange differences on translation of foreign operations	-	-	-	55	-	-	55	-	55
Total comprehensive loss for the period	-	-	-	55	-	(5,423)	(5,368)	(2,588)	(7,956)
At 30 June 2023	<u>144,707</u>	<u>124,672</u>	<u>47,978</u>	<u>(97)</u>	<u>(1,005)</u>	<u>(115,774)</u>	<u>200,481</u>	<u>25,670</u>	<u>226,151</u>

* These reserve accounts comprise the consolidated reserves of RMB52,475,000 and RMB65,680,000 in the consolidated statement of financial position as at 30 June 2024 and 31 December 2023, respectively.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2024

	Six months ended	
	30 June	
	2024	2023
	Unaudited	Unaudited
	<i>RMB'000</i>	<i>RMB'000</i>
Net cash flows used in operating activities	(28,956)	(21,278)
Net cash flows used in investing activities	(927)	(2,663)
Net cash flows from financing activities	1,549	1,369
	<hr/>	<hr/>
Net decrease in cash and cash equivalents	(28,334)	(22,572)
Cash and cash equivalents at beginning of period	63,410	77,349
	<hr/>	<hr/>
Cash and cash equivalents at end of period	35,076	54,777
	<hr/> <hr/>	<hr/> <hr/>

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PREPARATION

The unaudited condensed consolidated financial statements for the six months ended 30 June 2024 have been prepared in accordance with Hong Kong Financial Reporting Standards (“HKFRSs”) (which include all Hong Kong Financial Reporting Standards, Hong Kong Accounting Standards (“HKASs”) and Interpretations) issued by the Hong Kong Institute of Certified Public Accountants, accounting principles generally accepted in Hong Kong and the disclosure requirements of the Hong Kong Companies Ordinance. The accounting policies and basis of preparation used in the preparation of the unaudited condensed consolidated financial statements are consistent with those used in the Company’s audited financial statements for the year ended 31 December 2023.

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the condensed consolidated financial information are consistent with those applied in the preparation of the Group’s annual consolidated financial statements for the year ended 31 December 2023, except for the adoption of the following revised HKFRSs for the first time for the current period’s financial information.

Amendments to HKFRS 16	<i>Lease Liability in a Sale and Leaseback</i>
Amendments to HKAS 1	<i>Classification of Liabilities as Current or Non-current</i>
Amendments to HKAS 1	<i>Non-current Liabilities with Covenants</i>
Amendments to HKAS 7 and HKFRS 7	<i>Supplier Finance Arrangements</i>

The adoption of the above revised HKFRSs has had no significant financial effect on this unaudited condensed consolidated financial information and there has been no significant changes to the accounting policies applied in this unaudited condensed consolidated financial information.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group has one reportable operating segment: the in-vitro diagnostic (“IVD”) reagent products segment, which manufactures, sells and distributes a variety of mono/double diagnostic reagent products.

Management monitors the operating results of the Group’s business units as a whole for the purpose of making decisions about resources allocation and performance assessment. All of the Group’s revenue from external customers and profits are generated from this single segment.

Geographical information

During the six months ended 30 June 2024, 92% of the Group’s revenue was generated from customers located in mainland China and all of the non-current assets of the Group were located in mainland China.

Information about major customers

Revenue of approximately RMB11.1 million was derived from sales by the IVD reagent products segment to the largest customer of the Group, which accounted for 8% of the Group’s total revenue.

4. REVENUE

An analysis of the Group's revenue is as follows:

	Six months ended 30 June	
	2024	2023
	Unaudited RMB'000	Unaudited RMB'000
Sale of in-vitro diagnostic reagent products	133,049	138,138
Other service	360	848
Rental income	419	160
	<u>133,828</u>	<u>139,146</u>

5. LOSS FROM OPERATING ACTIVITIES

The Group's loss from operating activities is arrived at after charging/(crediting):

	Six months ended 30 June	
	2024	2023
	Unaudited RMB'000	Unaudited RMB'000
Cost of inventories sold and services provided	75,297	72,470
Foreign exchange differences, net	9	(169)
Depreciation of property, plant and equipment	7,790	8,894
Depreciation of investment properties	361	361
Amortisation of other intangible assets	1,562	1,542

For the six months ended 30 June 2024, the amortisation of other intangible assets amounted to approximately RMB1,562,000 (2023: approximately RMB1,542,000) which included (a) administrative expenses of approximately RMB1,197,000 (2023: approximately RMB1,179,000), (b) research and development expenses of approximately RMB296,000 (2023: approximately RMB296,000), (c) cost of sales of approximately RMB49,000 (2023: approximately RMB49,000) and (d) selling and distribution expenses of approximately RMB20,000 (2023: approximately RMB18,000).

6. INCOME TAX EXPENSE

Taxes on profits assessable in the People's Republic of China ("PRC" or "China"), where the Group operates, have been calculated at the rate of tax prevailing in the PRC. Under the PRC income tax laws, enterprises are subject to corporate income tax ("CIT") at a rate of 25%.

The Company and its two subsidiaries, Beijing Zhongsheng Jinyu Diagnostic Technology Co., Ltd. and Biosino Suzhou Medical Technology Co., Ltd., are entitled to a preferential rate of 15% under the PRC income tax laws for a period of three years commencing on 26 October 2023, 26 October 2022 and 3 November 2021, respectively, as they are accredited by the relevant government authorities as high and new technology enterprises.

No Hong Kong profits tax has been provided because the Group did not generate any assessable profits in Hong Kong during the period.

	Six months ended 30 June	
	2024	2023
	Unaudited	Unaudited
	RMB'000	RMB'000
Current – the PRC		
Charge for the period	2,212	1,841
Deferred	(43)	360
	<u>2,169</u>	<u>2,201</u>
Total tax charge for the period	<u>2,169</u>	<u>2,201</u>

7. LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS OF THE COMPANY

The calculation of basic loss per share for the six months ended 30 June 2024 is based on the unaudited loss attributable to shareholders of the Company for the period and the weighted average number of 144,707,176 (2023: 144,707,176) ordinary shares in issue during the period.

No adjustment has been made to the basic loss per share amounts presented for the six months ended 30 June 2024 and 2023 as the Group had no potentially dilutive ordinary shares in issue during those periods.

8. INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended 30 June 2024 (2023: Nil).

9. TRADE AND BILLS RECEIVABLES

The Group's customers include established customers and distributor customers. The established customers represent the hospital customers which purchased the Group's products for clinical, physical examination or scientific research uses. Except for certain established customers of the Group, which have been granted with payment terms ranging from four to twelve months, the credit periods of the Group granted to its customers are generally three months. The Group seeks to maintain strict control over its outstanding receivables and overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade receivable balances. Trade receivables are non-interest-bearing.

An aged analysis of the trade receivables of the Group as at the end of the Reporting Period, based on invoice date and net of loss allowance, is as follows:

	30 June	31 December
	2024	2023
	Unaudited	Audited
	RMB'000	RMB'000
Within 3 months	30,951	51,665
4 to 6 months	24,000	26,315
7 to 12 months	41,548	38,179
1 to 2 years	50,982	55,167
Over 2 years	30,037	8,472
	<u>177,518</u>	<u>179,798</u>

10. TRADE PAYABLES

An aged analysis of trade payables of the Group as at the end of the Reporting Period, based on the invoice date, is as follows:

	30 June 2024 Unaudited RMB'000	31 December 2023 Audited RMB'000
Within 3 months	14,687	26,827
4 to 6 months	11,912	10,299
7 to 12 months	22,061	12,142
1 to 2 years	13,347	22,204
Over 2 years	46,510	40,068
	<u>108,517</u>	<u>111,540</u>

The trade payables are non-interest-bearing and are normally settled on credit terms ranging from 30 days to 90 days. The balance with aging over 1 year is generally due to the extended credit terms granted by vendors to the Group.

11. INTEREST-BEARING BANK AND OTHER BORROWINGS

	30 June 2024 Unaudited RMB'000	31 December 2023 Audited RMB'000
Bank loans		
Unsecured	27,970	34,970
Secured	101,400	75,200
	<u>129,370</u>	<u>110,170</u>
Other loans		
Unsecured	5,000	5,000
Secured	6,942	27,547
	<u>11,942</u>	<u>32,547</u>
Total bank and other borrowings	141,312	142,717
Portion classified as current liabilities	<u>(136,382)</u>	<u>(140,737)</u>
Non-current portion	<u>4,930</u>	<u>1,980</u>

12. SHARE CAPITAL

	30 June 2024 Unaudited RMB'000	31 December 2023 Audited RMB'000
Registered, issued and fully paid:		
80,421,033 (2023: 80,421,033) domestic shares of RMB1 each	80,421	80,421
64,286,143 (2023: 64,286,143) H shares of RMB1 each	64,286	64,286
	144,707	144,707

13. CONTINGENT LIABILITIES

The guarantees given to a security company in connection with loans granted to a subsidiary were RMB6 million as at 30 June 2024 (31 December 2023: RMB10 million).

14. COMMITMENTS

On 9 December 2004, the Company and its substantial shareholder, Institute of Biophysics (“IBP”) of Chinese Academy of Science, entered into an exclusive technology licensing agreement (the “Licensing Agreement”) with regard to the production of diagnostic reagents by employing the technologies owned by IBP. Pursuant to the Licensing Agreement, the Company is required to pay a fee of RMB500,000 per annum to IBP for 20 years, commencing on the effective date of the Licensing Agreement. As at 30 June 2024, the technical service fees payable by the Group of RMB4,250,000 (31 December 2023: RMB4,000,000) were included in the other payables and accruals in the financial statements.

15. RELATED PARTY TRANSACTIONS

(a) The Group had the following material transactions with related parties during the period:

		Six months ended 30 June	
		2024	2023
	<i>Note</i>	Unaudited RMB'000	Unaudited RMB'000
Technical service fee to IBP	<i>(i)</i>	250	250
Sales of products			
Anhui Guoke Kangyi Medical Technology Co., Ltd.	<i>(ii)</i>	859	502
Purchase of products and materials			
Anhui Guoke Kangyi Medical Technology Co., Ltd.	<i>(ii)</i>	750	2,997
Interest expense			
Anhui Guoke Kangyi Medical Technology Co., Ltd.	<i>(ii)</i>	–	79

(b) Outstanding balances with related parties:

		30 June	31 December
		2024	2023
		Unaudited	Audited
	<i>Note</i>	RMB'000	RMB'000
Other payables			
IBP	<i>(i)</i>	4,250	4,000
Anhui Guoke Kangyi Medical Technology Co., Ltd.	<i>(ii)</i>	–	100
Other receivables			
Tashi Biotechnology (Suzhou) Co., Ltd.	<i>(iii)</i>	–	1,500
Trade receivables			
Anhui Guoke Kangyi Medical Technology Co., Ltd.	<i>(ii)</i>	–	78
Trade payables			
Anhui Guoke Kangyi Medical Technology Co., Ltd.	<i>(ii)</i>	–	616
		<u>–</u>	<u>616</u>

(c) Compensation of key management personnel of the Group

	Six months ended 30 June	
	2024	2023
	Unaudited	Unaudited
	RMB'000	RMB'000
Short-term employee benefits	2,809	2,933
Post-employment benefits	224	212
	<u>3,033</u>	<u>3,145</u>

The directors are of the opinion that the above transactions were conducted in the ordinary course of business of the Group.

Notes:

- (i) Details of the technical service fee are set out in note 14 to the interim report.
- (ii) Anhui Guoke Kangyi Medical Technology Co., Ltd. (“Anhui Guoke”) was controlled by Chen Peng, an executive director of the Group, until Anhui Guoke was disposed of to an independent third party on 1 April 2024. The Group borrowed RMB2 million from Anhui Guoke in January 2023, and repaid in November 2023 with the interest rate at 8%. The sales and purchase from Anhui Guoke (up until 31 March 2024) constituted continuing connected transactions as defined in Listing Rules.
- (iii) Tashi Biotechnology (Suzhou) Co., Ltd. (“Tashi Suzhou”) was directly held by Chen Peng, an executive director of the Group with the shareholding of 19%. On 26 December 2023, the Group provided a loan to Tashi Suzhou amounted to RMB1.5 million. The loan was collected on 8 January 2024 with no interest incurred.

16. APPROVAL OF THE FINANCIAL STATEMENTS

The condensed financial statements were approved and authorised for issue by the Board on 29 August 2024.

MANAGEMENT DISCUSSION AND ANALYSIS

Business Environment

In the first half of 2024, domestic routine diagnosis and treatment projects gradually resumed their normal state as the pandemic prevention and detection business subsided. Meanwhile, in China, the centralised procurement of IVD has entered the implementation stage, with a focus on quality improvement and market expansion. Due to the combined effects of environmental and policy changes, the IVD industry is facing multiple challenges and opportunities. Intensified market competition, policy changes, technological innovation and other factors are reshaping the industry landscape.

On one hand, aging population, growing chronic diseases, increased government investment in medical and health care and technological advancement are the ongoing driving forces for the development of IVD enterprises in China. On the other hand, the promotion of volume-based procurement and intensified market competition have led to lower terminal prices for IVD products, while the market demands increasingly higher product quality. These factors have further compressed the profits of enterprises and imposed higher requirements on management and operational capabilities.

In the first half of the year, facing a complex and changing business environment, the Company took a sober stance and remained committed to steady operations. Adhering to the quality policy of “high-quality, efficient, creating high-quality reagents, accurate, stable, and measuring life functions”, we continuously improved product quality. Upholding the principle of “product-centric and market-oriented”, the Company diversified its product pipeline, increased research and development investments, and released high-end scientific research for the SinoCyte flow cytometer (流式細胞儀). At the same time, we enhanced internal management and achieved the effects of quality improvement, cost reduction, and efficiency enhancement by improving the performance evaluation regime, calibrating internal processes, and implementing stringent process management.

Revenue

During the six months ended 30 June 2024 (the “Reporting Period”), the Group’s revenue from its principal businesses amounted to approximately RMB133.8 million, representing a decrease of approximately 3.8% when compared with that of approximately RMB139.1 million for the six months ended 30 June 2023 (the “Corresponding Period”). This decline was mainly due to the widespread implementation of centralised procurement and sales of medical consumables during the period, particularly the centralised procurement of liver function items across multiple sales outlets. The centralised procurement significantly impacted sales prices, whereas the increase in sales volume was insufficient to offset the effects brought by the price drops. In addition, the national medical insurance cost control policies also had an impact on the Group’s revenue.

Gross Profit and Gross Profit Margin

The gross profit during the Reporting Period was approximately RMB58.5 million, representing a decrease of approximately 12.3% as compared with that of approximately RMB66.7 million for the Corresponding Period and the gross profit margin was approximately 44% (Corresponding Period: approximately 48%). The decrease in gross profit and gross profit margin was mainly due to the impact of the decrease in sales prices of self-produced reagents as a result of the centralised procurement, whereas the increase in sales volume was insufficient to offset the effects brought by the price drops, as well as the structural change in which products with lower gross profit margins account for a rising proportion of the Group's overall revenue.

Selling and Distribution Expenses

During the Reporting Period, selling and distribution expenses were approximately RMB31.6 million, increased by approximately 2.9% as compared with that of approximately RMB30.7 million for the Corresponding Period. The increase in such expenses was primarily attributable to stronger sales efforts.

Administrative Expenses

During the Reporting Period, administrative expenses were approximately RMB22.3 million, decreased by approximately 13.6% as compared with that of approximately RMB25.8 million for the Corresponding Period. The decrease in such expenses was primarily attributable to the tightening cost control.

Research and Development Costs

During the Reporting Period, the Company invested approximately RMB16.9 million in R&D, representing an increase of approximately 5.6% as compared with that of approximately RMB16.0 million for the Corresponding Period. The Company has renewed the registration of 50 Class II products, including r-Glutamyltransferase Test Kit (GCANA Substrate Method), and has successfully developed 9 products, which are in the registration process, including β 2-microglobulin Test kit (Latex Immunoturbidimetry Method).

Loss for the Period

As a result, loss for the Reporting Period amounted to approximately RMB18.3 million, as compared to a loss of approximately RMB8.0 million for the Corresponding Period.

Future Prospects

China is one of the world's largest and fastest-growing IVD markets and an essential strategic hub in the global IVD market. According to a McKinsey report, China's healthcare technology industry has achieved rapid and remarkable development over the past decade, not only promoting progressive innovations in diagnosis and treatment but also making vital contributions to improving the health of Chinese citizens and advancing national economic development. In 2023, China IVD market size reached USD5,855 million, accounting for approximately 6% of the global IVD market size. It is expected that the market size will reach USD7,960 million by 2028, with a CAGR of approximately 6% from 2023 to 2028, much higher than that of the global IVD market of approximately 3.8%.

While the IVD industry maintains a robust development, the centralised procurement is also thriving in various provinces across the country, which involves a wide range of categories with ever-expanding scope of influence and experiences an accelerated substitution of domestic IVD. At the same time, various localities introduced development plans to encourage the development of medical equipment industry by providing support in the terms of assessment and approval, hospital application and medical insurance payment. In the second half of the year, the IVD industry will embrace more development opportunities and market potential despite the challenges.

In the second half of 2024, the Company will continue to consolidate its main business, improve quality and lower costs, broaden sources of revenue and reduce expenditure, thereby pursuing progress amidst adversities. First of all, we will maintain the quality strength of traditional biochemical diagnostic products to boost its sales volume and minimize the impact of centralised procurement prices. Secondly, we will strengthen the layout and marketing of multi-pipeline products, such as flow cytometry instruments and reagents, chemiluminescent instruments and reagents, and molecular diagnostic products. Meanwhile, in terms of operation management, on one hand, we will improve internal control management, optimise the production process, and reduce production costs, while keeping abreast of the industry development trend and exploring more potential business growth points to expand our revenue sources by arranging layout in advance for potential new businesses on the other hand.

Capital Structure, Financial Position and Liquidity

The Group generally finances its operations with cash flows generated from sales, capital contributions from shareholders and bank and other borrowings. There was no new issue of shares and approximately RMB88.2 million of bank and other borrowings were obtained during the Reporting Period.

During the Reporting Period, the change of capital structure of the Company as compared with that of 31 December 2023 is as follows:

	30 June 2024 RMB'000	31 December 2023 RMB'000
Cash and bank balances	35,076	63,410
Short-term loans	136,382	140,737
Long-term loans	4,930	1,980
Net debt	106,236	79,307
Net debt equity ratio	50%	34%
Gearing ratio (total liabilities/total assets)	60%	59%

Foreign Currency Risk

The Group's businesses are mostly located in the PRC and most transactions are conducted in RMB, except that the Group occasionally purchases equipment and some IVD reagent products from overseas countries for resale in the PRC and there are administrative expenses incurred by the Canadian subsidiary. A small amount of cash denominated in Hong Kong dollar ("HKD") is placed in bank accounts in Hong Kong for payment of miscellaneous expenses such as professional fees incurred in Hong Kong.

Pledge of Assets of the Group

As at 30 June 2024, certain buildings with a net carrying amount of approximately RMB21.0 million and prepaid land lease payments with a net carrying amount of approximately RMB2.2 million were pledged to Beijing Zhongguancun Sci-tech Financing Guaranty Co., Ltd., which guaranteed the Group's two bank loans. One bank loan, amounting to RMB69.7 million in principal, is from Bank of Beijing Co., Ltd., and is due within one year. The other bank loan, amounting to RMB11.7 million in principal, is from Industrial Bank Co., Ltd., and is also due within one year. Certain buildings with a net carrying amount of approximately RMB20.4 million were mortgaged to a third party which provided guarantees for the Group, to obtain bank loans of RMB20 million in aggregate from China Construction Bank and Industrial and Commercial Bank of China. These loans are due within one year.

As of 30 June 2024, certain machinery with net carrying amounts of approximately RMB2.1 million and RMB0.5 million were pledged to third parties to secure loans granted to the Company which amounted to RMB2.5 million and RMB4.4 million. These loans are due in December 2024 and March 2027, respectively.

Capital Expenditure

During the six months ended 30 June 2024, the Group had total capital expenditures amounted to RMB13 million.

Contingent Liabilities

As at the end of the Reporting Period, contingent liabilities not provided for in the financial statements were as follows:

	30 June 2024 RMB'000	31 December 2023 RMB'000
Counter-guarantees given to a security company in connection with loans	<u>6,000</u>	<u>10,000</u>

Significant Investments Held, Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures, and Future Plans for Material Investments or Capital Assets

Save as disclosed in this announcement, there was no significant investments held, material acquisitions and disposals of subsidiaries and associates by the Company during the six months ended 30 June 2024. The Group will make every endeavor to keep abreast of the changing market conditions, proactively identify investment opportunities in order to broaden the revenue base of the Group, enhance its future financial performance and profitability. Moreover, the Group will seek generic strategic expansions through acquisition(s) of suitable target(s). We are confident in the future and committed to continuous growth of the Company.

Employees and Remuneration Policies

On 30 June 2024, the Group had a total of 554 full-time employees (30 June 2023: 530 employees) based in Hong Kong and the PRC. Total staff costs of the Group (including the Directors' and supervisors' remuneration) for the six months ended 30 June 2024 amounted to approximately RMB52.1 million (Corresponding Period: RMB47.7 million). The Group determines the emoluments of its staff and the Directors based on their qualifications and experience, performance and market rates, so as to maintain the remuneration of its staff and the Directors at a competitive level. The remuneration policy and package of the Group's employees are periodically reviewed. The Group participates in various defined contribution retirement plans and insurance schemes in compliance with its statutory obligations under the laws and regulations of the PRC and Hong Kong. The Board believes that employees are one of the most valuable assets of the Group who contribute significantly to the success of the Group. The Group recognises the importance of training of its staff and hence provides regular training for the Group's staff members to enhance their technical and product knowledge.

Other than the company secretary and a qualified accountant, the remaining employees of the Group are stationed in China.

Events after the Reporting Period

There were no significant event affecting the Company that have occurred after the Reporting Period and up to the date of this announcement.

OTHER INFORMATION

Directors', Supervisors' and Chief Executive's Interests in Shares and Underlying Shares

As at 30 June 2024, the interests of the Directors, supervisors or chief executive of the Company in the shares and underlying shares of the Company or any associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "SFO")), as recorded in the register required to be kept by the Company pursuant to section 352 of the SFO, or as required pursuant to Rules 5.46 to 5.68 of the GEM Listing Rules, to be notified to the Company and the Stock Exchange, were as follows:

Long position in shares of the Company:

Name	Number of the Company's domestic shares held	Percentage of the Company's domestic shares	Number of the Company's H shares held	Percentage of the Company's H shares	Percentage of the Company's total registered share capital
Mr. Wu Lebin	3,500,878	4.35%	–	–	2.42%
Mr. Chen Peng	11,330,334	14.09%	–	–	7.83%
Mr. Chen Zhengyong	10,000,000	12.43%	–	–	6.91%

Save as disclosed above, as at 30 June 2024, none of the Directors, supervisors or chief executive of the Company had registered an interest and short position in the shares and underlying shares of the Company or any of its associated corporations that was required to be recorded pursuant to Section 352 of the SFO, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to Rules 5.46 to 5.68 of the GEM Listing Rules.

Substantial Shareholders' and Other Persons' Interests in Shares and Underlying Shares

As at 30 June 2024, as far as is known to any Directors and supervisors of the Company, other than the interest of the Directors, supervisors and chief executive of the Company as disclosed under the section headed "Directors', Supervisors' and Chief Executive's Interests in Shares and Underlying Shares" above, the following persons had interests in the shares and underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO, or as otherwise notified to the Company and the Stock Exchange:

Long positions in shares of the Company:

Name	Capacity and nature of interest	Number of the Company's shares held		Percentage of the Company's respective type of shares		Percentage of the Company's total registered capital
		Domestic shares	H shares	Domestic shares	H shares	
Beijing Pusai Asset Management Co., Ltd. (北京普賽資產管理有限責任公司)	Directly beneficially owned	31,308,576	–	38.93%	–	21.64%
HK Zhixin Investment Co., Ltd. (Note 1)	Directly beneficially owned	–	27,256,143	–	42.40%	18.84%
Hainan Zhixin Investment Partnership (Limited Partnership) (Note 1)	Through controlled corporations	–	27,256,143	–	42.40%	18.84%
Mr. Li Dongfeng (Note 1)	Through controlled corporations	–	27,256,143	–	42.40%	18.84%
Mr. Yan Kang (Note 1)	Through controlled corporations	–	27,256,143	–	42.40%	18.84%
Yunan Shengneng Investment Partnership (Limited Partnership) (Note 2)	Directly beneficially owned	10,939,314	6,780,000	13.60%	10.55%	12.24%
Mr. Li Yangyixiong (Note 2)	Through controlled corporations	10,939,314	6,780,000	13.60%	10.55%	12.24%
	Directly beneficially owned	1,050,263	–	1.31%	–	0.73%
Jingning Guoke Kangyi Enterprise Management Center LLP (Note 3)	Directly beneficially owned	11,330,334	–	14.09%	–	7.83%
Sichuan Zhongsheng Medical Instrument Co., Ltd. (Note 4)	Directly beneficially owned	10,000,000	–	12.43%	–	6.91%
Chung Shek Enterprises Company Limited (Note 5)	Directly beneficially owned	–	3,800,000	–	5.91%	2.63%
K.C. Wong Education Foundation (Note 5)	Through controlled corporations	–	3,800,000	–	5.91%	2.63%

Notes:

1. HK Zhixin Investment Co., Ltd. (“HK Zhixin”) was wholly owned by Hainan Zhixin Investment Partnership (Limited Partnership), which was owned as to approximately 36.01% and 36.01% by Mr. Yan Kang and Mr. Li Dongfeng, respectively, as the limited partners. Accordingly, Mr. Yan Kang and Mr. Li Dongfeng were deemed to be interested in the H shares owned by HK Zhixin pursuant to the SFO.
2. Yunan Shengneng Investment Partnership (Limited Partnership) (“Yunan Shengneng”) was owned as to approximately 43.12% by Mr. Li Yangyixiong and seven other shareholders which none of them held more than one-third or more of the voting power at general meetings of Yunan Shengneng. Accordingly, Mr. Li Yangyixiong was deemed to be interested in the H shares and the domestic shares owned by Yunan Shengneng pursuant to the SFO.
3. The interests of Jingning Guoke Kangyi Enterprise Management Center LLP (“Jingning Guoke”) was owned as to 99.5% by Mr. Chen Peng, the president of the Company. Accordingly, Mr. Chen Peng is deemed to be interested in the domestic shares owned by Jingning Guoke pursuant to the SFO.
4. The equity interests of Sichuan Zhongsheng Medical Instrument Co., Ltd. (“Sichuan Zhongsheng”) were owned as to approximately 77.94% by Mr. Chen Zhengyong. Accordingly, Mr. Chen Zhengyong is deemed to be interested in the domestic shares owned by Sichuan Zhongsheng pursuant to the SFO.
5. Information is extracted from the corporate substantial shareholder notices filed by Chung Shek Enterprises Company Limited and K.C. Wong Education Foundation on 7 December 2010.

Save as disclosed above, as far as is known to any Directors or supervisors of the Company, as at 30 June 2024, no other persons, other than the Directors, supervisors and chief executive of the Company, whose interests are set out in the section headed “Directors’, Supervisors’ and Chief Executive’s Interests in Shares and Underlying Shares” above, had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO, or as otherwise notified to the Company and the Stock Exchange.

Directors’ and Supervisors’ Rights to Acquire Shares or Debentures

None of the Directors or supervisors or their respective associates (as defined under the GEM Listing Rules) was granted by the Company or its subsidiaries any rights or options to acquire any shares in or debentures of the Company or had exercised any such rights during the six months ended 30 June 2024.

Competing Interests

During the Reporting Period and up to the date of this announcement, none of the Directors, supervisors, the substantial shareholders of the Company and their respective close associates (as defined in the GEM Listing Rules) has an interest in any business that competes or may compete, either directly or indirectly, with the business of the Group, nor any conflicts of interest which has or may have with the Group.

Purchase, Sale or Redemption of the Company's Listed Securities

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the six months ended 30 June 2024.

Directors' Securities Transactions

The Group has adopted a model code of conduct for dealing in the Company's securities by the Directors, which was formulated in accordance with Rules 5.48 to 5.67 of the GEM Listing Rules (the "required standard of dealings") for the purpose of setting out the standards adopted by the Company for assessing the conduct of the Directors in their dealings in the securities of the Company. Any violation of this code will be regarded as a violation of the GEM Listing Rules. The Company has confirmed, after making specific enquiries with the Directors, that all Directors have complied with the required standard of dealings throughout the Reporting Period.

Audit Committee

The Company has established an audit committee (the "Audit Committee") with written terms of reference in compliance with the GEM Listing Rules. The Audit Committee's primary duties are the review and supervision of the Company's financial reporting procedures and internal control system. The Group's unaudited condensed consolidated financial statements for the Reporting Period have been reviewed by the Audit Committee with the four independent non-executive Directors, namely Mr. Lu Qi, Prof. Shen Zuojun, Prof. Shen Jiangang and Dr. He Xin, of which Mr. Lu Qi is the chairman.

Corporate Governance

The Company had applied the principles and all the applicable code provisions (the "Code Provisions") as set out under the Corporate Governance Code (the "CG Code") contained in Appendix C1 of the GEM Listing Rules during the Reporting Period and up to the date of this announcement. The Directors will periodically review the Company's corporate governance policies and will propose any amendment, if necessary, to ensure compliance with the Code Provisions from time to time.

During the Reporting Period and up to the date of this announcement, the Company had complied with all the applicable Code Provisions of the CG Code, except for Code Provision D.2.5 of the CG Code as explained below:

Code Provision D.2.5 states that the Company should have an internal audit function. Based on the size and simple operating structure of the Group as well as the internal control processes, the Group decided not to set up an internal audit department for the time being. However, the Board has put in place adequate measures to perform the internal audit function in relation to different aspects including (i) the Board has established formal arrangements to apply financial reporting and internal control principles in accounting and financial matters to ensure compliance with the GEM Listing Rules and all relevant laws and regulations and (ii) the Company engaged an external consultant to perform an internal review on the scope determined by the Audit Committee. The Company considers that the existing organisation structure and close supervision by the management and the abovementioned engagement of the external consultant can maintain sufficient risk management and internal control of the Group. The Board will review the need to set up an internal audit function from time to time and may set up an internal audit team if the need arises.

Non-Compliance with the GEM Listing Rules

On 9 May 2024, the Company announced that the transactions between the Group with Anhui Guoke Kangyi Medical Technology Co., Ltd.* (安徽國科康儀醫療科技有限公司) (“Anhui Guoke”) in relation to (i) the sales of reagent products and the purchases of test reagents and consumables with an aggregate consideration of approximately RMB16.99 million (equivalent to approximately HK\$18.69 million) during the year ended 31 December 2022 when aggregated together constituted non-exempt continuing connected transactions of the Company under Chapter 20 of the GEM Listing Rules; (ii) the sales of reagent products and the purchases of test reagents and consumables with an aggregate consideration of approximately RMB5.05 million (equivalent to approximately HK\$5.56 million) during the year ended 31 December 2023 when aggregated together constituted non-exempt continuing connected transactions of the Company under Chapter 20 of the GEM Listing Rules; and (iii) the sales of reagent products and the purchases of test reagents and consumables with an aggregate consideration of approximately RMB1.61 million (equivalent to approximately HK\$1.77 million) during the three months ended 31 March 2024 when aggregated together constituted exempt continuing connected transactions of the Company under Rule 20.74 of the GEM Listing Rules.

Due to an inadvertent oversight, the Company did not comply with the relevant requirements of the GEM Listing Rules at the material time. Accordingly, there has been an inadvertent non-compliance by the Company of Chapter 20 of the GEM Listing Rules.

Following the disposal of 51% of the equity interest in Anhui Guoke by Jingning Guoke Kangyi Enterprise Management Centre (Limited Partnership)* (景寧國科康儀企業管理中心(有限合伙)) to an independent third party on 1 April 2024, Anhui Guoke ceased to be a connected person of the Company. As such, the future transactions between Anhui Guoke and the Group are no longer connected transactions of the Group as defined in the GEM Listing Rules. For details, please refer to the announcements of the Company dated 9 May 2024 and 27 May 2024.

* For identification purpose only

Updated Information of Director Pursuant to Rule 17.50A(1) Of the GEM Listing Rules

After having made all reasonable enquiries, the Board is not aware of any information required to be disclosed pursuant to Rule 17.50A(1) of the GEM Listing Rules during the Reporting Period.

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman

Beijing, the PRC, 29 August 2024

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and non-executive Directors

Mr. Yang Peng (楊鵬先生) and Mr. Chen Zhengyong (陳正永先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生), Prof. Shen Jiangang (沈劍剛教授) and Dr. He Xin (何欣博士)

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least seven days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.